Literature DB >> 15529265

Antiretrovirals as antimalarial agents.

Tina S Skinner-Adams1, James S McCarthy, Donald L Gardiner, Petrina M Hilton, Katherine T Andrews.   

Abstract

Recent studies have indicated that antiretroviral protease inhibitors may affect outcome in malarial disease. We have investigated the antimalarial activities of 6 commonly used antiretroviral agents. Our data indicate that, in addition to the previously published effects on cytoadherence and phagocytosis, the human immunodeficiency virus (HIV)-1 protease inhibitors saquinavir, ritonavir, and indinavir directly inhibit the growth of Plasmodium falciparum in vitro at clinically relevant concentrations. These findings are particularly important in light of both the high rate of malaria and HIV-1 coinfection in sub-Saharan Africa and the effort to employ highly active antiretroviral therapy in these regions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529265     DOI: 10.1086/425584

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  63 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.

Authors:  T S Skinner-Adams; K T Andrews; L Melville; J McCarthy; D L Gardiner
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.

Authors:  Sunil Parikh; Jun Liu; Puran Sijwali; Jiri Gut; Daniel E Goldberg; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.

Authors:  Zhengxiang He; Li Qin; Lili Chen; Nanzheng Peng; Jianlan You; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

6.  Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.

Authors:  Paul Natureeba; Veronica Ades; Flavia Luwedde; Julia Mwesigwa; Albert Plenty; Pius Okong; Edwin D Charlebois; Tamara D Clark; Bridget Nzarubara; Diane V Havlir; Jane Achan; Moses R Kamya; Deborah Cohan; Grant Dorsey
Journal:  J Infect Dis       Date:  2014-06-23       Impact factor: 5.226

7.  Buy one, get one free? Benefits of certain antiretrovirals against malaria.

Authors:  Charlotte V Hobbs; Sunil Parikh
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

8.  Asexual and sexual stages of Plasmodium falciparum in Nigerian pregnant women attending antenatal booking clinic.

Authors:  S T Balogun; F A Fehintola; O A Adeyanju; A A Adedeji
Journal:  Obstet Med       Date:  2010-09-17

9.  Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

Authors:  Jane M Sayer; John M Louis
Journal:  Proteins       Date:  2009-05-15

10.  HIV treatments have malaria gametocyte killing and transmission blocking activity.

Authors:  Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.